Gilead Sciences (NASDAQ:GILD) Given New $75.00 Price Target at UBS Group

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target cut by research analysts at UBS Group from $81.00 to $75.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price objective points to a potential upside of 13.36% from the company's current price.

Several other research firms have also weighed in on GILD. Barclays lowered their price objective on Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday, February 12th. Truist Financial lowered Gilead Sciences from a "buy" rating to a "hold" rating and decreased their price target for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Oppenheimer decreased their price target on Gilead Sciences from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, February 12th. Royal Bank of Canada decreased their price target on Gilead Sciences from $76.00 to $75.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 14th. Finally, Mizuho decreased their price target on Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $84.71.

Gilead Sciences Stock Down 1.2 %

NASDAQ GILD traded down $0.77 during trading on Wednesday, hitting $66.16. 6,440,752 shares of the company traded hands, compared to its average volume of 7,307,979. Gilead Sciences has a 12 month low of $65.90 and a 12 month high of $87.86. The business has a fifty day simple moving average of $72.10 and a 200 day simple moving average of $76.58. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $82.37 billion, a P/E ratio of 14.70, a PEG ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period in the prior year, the firm posted $1.67 EPS. Gilead Sciences's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences will post 6.55 EPS for the current year.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company's stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of large investors have recently added to or reduced their stakes in GILD. Altfest L J & Co. Inc. bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $210,000. Federated Hermes Inc. raised its position in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company's stock valued at $306,814,000 after buying an additional 175,925 shares in the last quarter. Abundance Wealth Counselors acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,881,000. Toronto Dominion Bank raised its position in shares of Gilead Sciences by 66.6% in the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company's stock valued at $96,589,000 after buying an additional 515,191 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in Gilead Sciences by 8.9% during the fourth quarter. Mackenzie Financial Corp now owns 535,557 shares of the biopharmaceutical company's stock valued at $43,385,000 after purchasing an additional 43,630 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.